Different NT-proBNP circulating levels for different types of cardiac amyloidosis
暂无分享,去创建一个
S. Frusconi | F. Perfetto | F. Cappelli | F. Bergesio | G. Ciuti | E. Grifoni | A. Fabbri | V. Spini | Paola Angelotti
[1] P. Hawkins,et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. , 2014, European heart journal cardiovascular Imaging.
[2] S. Solomon,et al. Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis , 2014, Circulation.
[3] S. K. White,et al. Native T1 mapping in transthyretin amyloidosis. , 2014, JACC. Cardiovascular imaging.
[4] A. Wechalekar,et al. Imaging in systemic amyloidosis. , 2013, British medical bulletin.
[5] A. Petrie,et al. Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome , 2013, Journal of the American Heart Association.
[6] L. Padeletti,et al. Cardiac amyloidosis: the heart of the matter , 2013, Internal and Emergency Medicine.
[7] F. Salvi,et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.
[8] F. Perfetto,et al. Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany? , 2011, Journal of cardiovascular medicine.
[9] H. Katus,et al. Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis , 2009, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[10] R. Falk,et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. , 2009, American heart journal.
[11] F. Salvi,et al. Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types , 2009, Circulation.
[12] O. Cummings,et al. Biochemical characterisation of amyloid by endomyocardial biopsy , 2009, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[13] P. Lindqvist,et al. Do troponin and B‐natriuretic peptide detect cardiomyopathy in transthyretin amyloidosis? , 2008, Journal of internal medicine.
[14] F. Salvi,et al. Gender-related risk of myocardial involvement in systemic amyloidosis , 2008, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[15] William Stewart,et al. Recommendations for chamber quantification. , 2006, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[16] Richard B Devereux,et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[17] R. Falk. Diagnosis and Management of the Cardiac Amyloidoses , 2005, Circulation.
[18] F. Salvi,et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.
[19] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[20] R. Falk,et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.
[21] M. Skinner,et al. Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress , 2004, Circulation research.
[22] G. Palladini,et al. Widespread cardiovascular autonomic dysfunction in primary amyloidosis: does spontaneous hyperventilation have a compensatory role against postural hypotension? , 2002, Heart.
[23] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[24] H. Itoh,et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. , 1998, Journal of the American College of Cardiology.
[25] R. Falk,et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. , 1998, QJM : monthly journal of the Association of Physicians.
[26] R. Falk,et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. , 1997, Heart.
[27] J. Laragh,et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. , 1992, Journal of the American College of Cardiology.
[28] K. Sletten,et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[29] It Istituto Superiore di Sanit,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 , 2005 .
[30] R. Kyle,et al. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. , 1995, Seminars in hematology.